Investment Rating - The investment rating for Alibaba-SW (09988.HK) is "Outperform the Market" [6][24]. Core Insights - Alibaba's overall performance shows weak e-commerce results while cloud revenue continues to accelerate. For FY26Q3, Alibaba reported revenue of 284.8 billion yuan, a year-on-year increase of 2%. The revenue growth rates for different segments were 6% for the China e-commerce group, 4% for the international digital commerce group, 36% for the cloud intelligence group, and -20% for all others [1][9]. - The adjusted EBITA for FY26Q3 was 23.4 billion yuan, down 57% year-on-year, with an adjusted EBITA margin of 8.2%. The non-GAAP net profit was 16.7 billion yuan, a decrease of 67% year-on-year, resulting in a net profit margin of 5.9%. Free cash flow for the quarter was 11.3 billion yuan, down 71% year-on-year, primarily due to investments in instant retail [1][9]. Summary by Sections E-commerce Performance - The China e-commerce group's revenue for FY26Q3 increased by 1% year-on-year, with a significant decline in quarter-on-quarter growth due to base effects from improved monetization rates and weak market performance. Instant retail revenue reached 20.8 billion yuan, up 56% year-on-year. The company added approximately 150 million annual active buyers on the platform, with about 100 million in physical e-commerce [2][14]. - The adjusted EBITA for the China e-commerce group was 34.6 billion yuan, down 43% year-on-year, with an adjusted EBITA margin of 22%, a decline of 19 percentage points year-on-year. The estimated loss from the instant retail business for the quarter was around 20.8 billion yuan [2][14]. Cloud Computing - The cloud intelligence group's revenue for FY26Q3 was 43.3 billion yuan, a year-on-year increase of 36%. The overall revenue, excluding intercompany transactions, grew by 35% year-on-year. AI-related product revenue continued to grow at triple-digit rates. Alibaba Cloud's market share has increased for three consecutive quarters, reaching 36% [3][16]. - The company expects external revenue from cloud and AI, including MaaS, to exceed 100 billion USD over the next five years, with a compound annual growth rate of over 40% [3][16]. Financial Projections - Revenue forecasts for FY2026 to FY2028 have been slightly adjusted to 1,033.8 billion yuan, 1,165.4 billion yuan, and 1,318.8 billion yuan, reflecting a positive outlook on cloud revenue growth. Adjusted net profit forecasts have been revised to 79.7 billion yuan, 105.7 billion yuan, and 134.3 billion yuan, primarily due to higher-than-expected R&D and marketing investments related to Qianwen and e-commerce [4][25].

Investment Rating - The report maintains an "Outperform" rating for Giant Biogene with a target price of HKD 36.20, implying a potential upside of 17.9% from the current price of HKD 30.70 [2][3]. Core Insights - The company’s 2025 results were broadly in line with expectations, with total revenue of RMB 5.52 billion, a slight decline of 0.4% year-on-year. The attributable net profit was RMB 1.91 billion, down 7.1% year-on-year, but exceeded estimates by 2.1% [4][15]. - Revenue for 2026 is projected to grow to RMB 6.06 billion, representing a year-on-year increase of 9.8%, with net profit expected to reach RMB 2.00 billion, reflecting a growth of 4.6% [3][14]. - The company is focusing on the commercialization of its medical aesthetics business, with two Class III medical device products approved and set to launch in 2026. This is expected to create a dual-growth engine alongside its skincare products [6][17]. Financial Performance - For 2025, the gross margin was 80.3%, down 1.8 percentage points year-on-year, while the net profit margin was 34.7% [4][15]. - The company’s revenue breakdown shows functional skincare products generated RMB 4.34 billion, a 0.8% increase year-on-year, while medical dressings fell to RMB 1.16 billion, a decline of 4.8% [4][15]. - The report highlights a healthy balance sheet with cash and cash equivalents of RMB 6.31 billion as of the end of 2025, and no interest-bearing debt [19]. Product Performance - The KomfyMed brand saw a slight revenue decline of 1.6% to RMB 4.47 billion, while the Collgene brand achieved a 9.2% increase to RMB 0.92 billion, driven by online channel expansion [5][16]. - The management has set clear targets for new product launches in 2026, including the Focus Series essence and Zhixu Series, with expectations for significant sales growth [8][18]. Market Outlook - The report anticipates that the company will return to growth in 2026, with a focus on new product performance and the medical aesthetics business as key drivers [3][14]. - The competitive landscape is noted to be intensifying, which may impact profit growth, leading to a revised P/E multiple of 17x for 2026 [3][14].

小鹏汽车（9868.HK）系列点评十 2025Q4 首次季度盈利 物理 AI 加速突破 glmszqdatemark 2026 年 03 月 23 日 [Table_Author] 分析师：崔琰 分析师：完颜尚文 执业证书：S0590525110023 执业证书：S0590525110027 邮箱：cuiyan@glms.com.cn 邮箱：wanyanshangwen@glms.com.cn 事件：公司发布 2025Q4 财报：2025 年全年收入为 767.2 亿元，同比+87.7%， 其中：2025Q4 收入 222.5 亿元，同比/环比分别为+38.2%/+9.2%。2025Q4 汽 车业务毛利率为+13.0%，同比/环比分别为+3.0pts/-0.1pts。2025Q4 Non- GAAP 归母净利润为+5.1 亿元，首次实现季度盈利。 毛利率再创新高 首次实现季度盈利 营收端：2025Q4 实现单季营收入 222.5 亿元，同比/环比分别为+38.2%/+9.2%。 其中 2025Q4 汽车业务收入为 190.7 亿元，同比/环比分别为+30.0%/+5.6%， 主要由于交付量增加所致。2025Q ...

Investment Rating - The investment rating for Alibaba-W (09988.HK) is "Buy" (maintained) [1][29] Core Views - The company's FY26Q3 performance was below market expectations, with total revenue of RMB 284.84 billion, a year-on-year increase of 2%, which was lower than the consensus estimate of RMB 289.79 billion. Adjusted net profit was RMB 16.71 billion, a year-on-year decline of 67%, also below the expected RMB 29.58 billion. The main pressure on performance came from weak growth in the Chinese e-commerce business and significant investments in user experience, instant retail, and AI-related initiatives [12][19] - The cloud and AI segments continue to accelerate, with the Cloud Intelligence Group reporting revenue of RMB 43.28 billion, a year-on-year increase of 36%. The growth was driven by public cloud revenue and increased adoption of AI-related products. The company is advancing its "AI + Cloud" strategy across various segments, including high-performance networks and distributed storage [23][26] Summary by Sections Revenue Performance - The company's revenue performance was weak, with total revenue of RMB 284.84 billion in FY26Q3, a 2% year-on-year increase, falling short of market expectations. Adjusted net profit was RMB 16.71 billion, down 67% year-on-year [12][19] - The Chinese e-commerce group's revenue grew by 6% to RMB 159.35 billion, while customer management revenue (CMR) increased by only 1% to RMB 102.66 billion, reflecting a slowdown due to macroeconomic factors [16][19] E-commerce Business - The e-commerce main business showed stable performance, with instant retail maintaining high growth. Instant retail revenue grew by 56% to RMB 20.84 billion, making it the fastest-growing segment within the e-commerce group [20][21] - CMR growth has slowed, leading to temporary pressure on profitability, with adjusted EBITA margin at 22%, down 19 percentage points year-on-year [19][20] Cloud and AI Growth - The Cloud Intelligence Group continued its high growth trajectory, with revenue increasing by 36% to RMB 43.28 billion. The adjusted EBITA margin was 9%, driven by public cloud revenue growth and increased adoption of AI products [23][26] - The company is focusing on integrating AI with cloud services, enhancing capabilities in model training and inference, and has seen significant growth in AI-related product revenue [23][26] Earnings Forecast and Valuation - Due to the underperformance in FY26Q3, the forecast for Non-GAAP net profit for FY2026, FY2027, and FY2028 has been adjusted to RMB 78.88 billion, RMB 105.40 billion, and RMB 138.45 billion, respectively. The corresponding PE (Non-GAAP) ratios are projected to be 26.4, 19.7, and 15.0 times [26][29] - Despite the challenges, the cloud and AI segments remain the core growth drivers for the company, and it continues to be the largest online retail platform in the market, justifying the "Buy" rating [29]

Investment Rating - The investment rating for Geely Automobile is "Buy" (maintained) [1] Core Views - The Q4 performance of Geely Automobile is generally in line with expectations, with total revenue of 105.76 billion yuan, representing a year-on-year increase of 22.1% and a quarter-on-quarter increase of 18.6%. The net profit attributable to the parent company is approximately 3.74 billion yuan, showing a slight decline of 1.9% year-on-year and 2.0% quarter-on-quarter [8] - The company aims for a sales target of 3.45 million vehicles in 2026, which is a year-on-year increase of 14%. The new vehicle lineup includes models such as Zeekr 8x and Lynk & Co 07 [8] - The forecast for net profit attributable to the parent company for 2026 has been raised to 20.8 billion yuan, up from the previous estimate of 19.5 billion yuan, reflecting strong performance in high-end models and exports [8] Financial Summary - Total revenue projections for Geely Automobile are as follows: - 2024: 240.19 billion yuan - 2025: 345.23 billion yuan (up 43.73% year-on-year) - 2026: 412.87 billion yuan (up 19.59% year-on-year) - 2027: 476.83 billion yuan (up 15.49% year-on-year) - 2028: 518.64 billion yuan (up 8.77% year-on-year) [1] - Net profit attributable to the parent company is projected as follows: - 2024: 16.63 billion yuan - 2025: 16.85 billion yuan (up 1.32% year-on-year) - 2026: 20.80 billion yuan (up 23.44% year-on-year) - 2027: 24.44 billion yuan (up 17.51% year-on-year) - 2028: 28.19 billion yuan (up 15.33% year-on-year) [1] - The latest diluted EPS is projected to be: - 2024: 1.54 yuan - 2025: 1.56 yuan - 2026: 1.92 yuan - 2027: 2.26 yuan - 2028: 2.60 yuan [1]

Investment Rating - The report assigns a BUY rating to SANY International with a target price of HK$20.60, indicating a potential upside of 72.2% from the current price of HK$11.96 [4][5]. Core Insights - SANY International's after-tax profit for 2025 is expected to grow by 50-73% YoY to RMB1.6-1.85 billion, primarily due to a significant reduction in impairment losses. However, on a recurring basis, profit is projected to decline by 10% to grow by 4% YoY, falling 16-27% below estimates and 19-30% below Bloomberg consensus [1]. - The negative earnings surprise is attributed to one-off expenses related to port equipment and higher-than-expected operating expenses in the solar power segment. Despite the anticipated weak earnings in 2025, a strong recovery is expected in 2026, driven by robust orders for mining trucks and favorable conditions in the oil and gas equipment segment [1]. Financial Summary - Revenue is projected to grow from RMB20.3 billion in FY23 to RMB34.8 billion in FY27, reflecting a CAGR of 16.9% [3][12]. - Adjusted net profit is expected to increase from RMB1.9 billion in FY23 to RMB3.7 billion in FY27, with a notable growth of 30.8% in FY26 [3][12]. - The P/E ratio is forecasted to decrease from 17.3x in FY23 to 9.3x in FY27, indicating a more attractive valuation over time [3][12]. - The company is expected to maintain a dividend yield that increases from 1.7% in FY23 to 4.3% in FY27 [3][12]. Share Performance - The market capitalization of SANY International is approximately HK$38.65 billion, with a 52-week high of HK$15.97 and a low of HK$4.42 [5][6]. - The stock has shown a significant performance increase over the past six months, with a rise of 68.5% [7]. Shareholding Structure - Sany Heavy Equipment holds a 64.9% stake in SANY International, indicating a strong controlling interest [6]. Operating Assumptions - The revenue from mining trucks is expected to grow from RMB4.1 billion in 2025 to RMB5.9 billion in 2027, reflecting a strong demand in this segment [11]. - The oil and gas equipment segment is projected to benefit from high commodity prices, contributing positively to overall revenue growth [1]. Conclusion - SANY International is positioned for growth with a strong outlook for 2026, despite short-term challenges in 2025. The company's strategic focus on mining trucks and oil & gas equipment, along with a favorable valuation, supports the BUY rating [1][3][4].

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Insights - The company reported a strong performance in its annual report for 2025, with revenue of 29.6 billion, a year-on-year increase of 3.2%, and a net profit of 2.94 billion, down 2.6% year-on-year, but exceeding market expectations [1] - The company is focusing on multiple product categories for growth, particularly in running and training segments, while also exploring opportunities in niche markets [4] - The company maintained a healthy inventory turnover and cash flow, with operating cash flow of 4.85 billion, showcasing strong financial health [3] Revenue Analysis - The running category remains the largest contributor, accounting for 31% of total revenue with a growth rate of 10%, while new categories like outdoor and Honor Gold Standard have increased their revenue share to 8% [2] - The wholesale channel saw a revenue increase of 6.3%, driven by growth in professional channels, while e-commerce revenue grew by 5.3% [2] - Direct sales revenue declined by 3.3% due to store adjustments and a net reduction in the number of stores [2] Profitability and Forecast - The company expects to maintain strong performance in 2026, with projected revenues of 31.7 billion, a year-on-year increase of 7.1%, and net profit of 3 billion, reflecting a 2% growth [4] - The projected P/E ratios for 2026, 2027, and 2028 are 16.2, 14.3, and 12.9 respectively, indicating a favorable valuation outlook [4]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has achieved operational efficiency improvements and a reduction in impairment losses, with national subsidy collection reaching a record high, leading to performance and dividend results that exceeded expectations [1] - The company's revenue for 2025 is projected at HKD 27.52 billion, a year-on-year decrease of 9%, while the net profit attributable to shareholders is expected to be HKD 3.93 billion, an increase of 16.23% year-on-year [1] - The report highlights a significant improvement in cash flow, with a free cash flow increase to HKD 10.13 billion in 2025, compared to HKD 4.04 billion in 2024, and a dividend payout ratio increase to 42.3% [1] Financial Performance Summary - Total revenue for 2025 is projected at HKD 27,521 million, with a year-on-year decline of 9.05% [9] - The net profit attributable to shareholders for 2025 is forecasted at HKD 3,925 million, reflecting a year-on-year growth of 16.23% [9] - Earnings per share (EPS) for 2025 is expected to be HKD 0.64, with a price-to-earnings (P/E) ratio of 8.03 [9] - The company’s total assets are projected to reach HKD 193,595.67 million by 2026, with a debt-to-asset ratio of 60.12% [9] Operational Highlights - The company has optimized its revenue structure, with operational revenue accounting for 72% of total revenue in 2025, up 8 percentage points year-on-year [8] - The environmental energy segment reported operational revenue of HKD 101.48 billion, a 4% increase, contributing significantly to the net profit [8] - The company has improved its receivables collection rate to over 98%, with national subsidy collection rate reaching 134% [8]

Investment Rating - The report maintains an "Outperform" rating for Giant Biogene with a target price of HKD 36.20, implying a potential upside of 17.9% from the current price of HKD 30.70 [2][3]. Core Insights - The company’s 2025 results were broadly in line with expectations, with total revenue of RMB 5.52 billion, a slight decline of 0.4% year-on-year. The attributable net profit was RMB 1.91 billion, down 7.1% year-on-year, but exceeded estimates by 2.1% [4][15]. - Revenue for 2026 is projected to grow to RMB 6.06 billion, representing a year-on-year increase of 9.8%, with attributable net profit expected to reach RMB 2.00 billion, reflecting a growth of 4.6% [3][14]. - The gross profit margin is expected to decline slightly from 80.3% in 2025 to 79.7% in 2026, while the net profit margin is projected to be 33.1% [10][14]. Financial Performance - The company achieved a gross margin of 80.3% in 2025, which was slightly below expectations, while the selling expense ratio was better than anticipated at 37.3% [4][15]. - Functional skincare products generated revenue of RMB 4.34 billion, growing 0.8% year-on-year, outperforming forecasts by 8.7%. In contrast, medical dressings saw a decline of 4.8% year-on-year to RMB 1.16 billion, falling short of projections by 21.6% [4][15][16]. Future Focus Areas - Key focus area 1 is the commercialization timeline and sales ramp-up of the medical aesthetics business, with two Class III medical device products approved and expected to launch in 2026. The company aims to leverage its network of approximately 4,700 hospitals and clinics [6][17]. - Key focus area 2 involves the sales performance of new products in 2026, particularly the Focus Series essence and the Zhixu Series. Management anticipates significant growth from these new launches, with specific sales targets set for the first year [8][18]. Balance Sheet and Dividends - As of the end of 2025, the company reported cash and cash equivalents of RMB 6.31 billion, a 56.5% increase year-on-year, with no interest-bearing debt. The total dividends declared for 2025 were RMB 1.29 billion, representing a payout ratio of approximately 67% [19].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company has achieved operational efficiency improvements and a reduction in impairment losses, with national subsidy collections reaching a record high, leading to performance and dividend results that exceeded expectations [1] - The company’s revenue for 2025 is projected at 27,521 million HKD, a decrease of 9.05% year-on-year, while the net profit attributable to shareholders is expected to rise by 16.23% to 3,925 million HKD [1] - The report highlights a significant increase in free cash flow and a dividend payout ratio increase to 42.3%, indicating strong potential for future dividends [1] Financial Summary - Revenue and Profit Forecasts: - Total revenue for 2024 is projected at 30,258 million HKD, decreasing to 27,521 million HKD in 2025, and further declining to 27,145 million HKD in 2026 [1] - Net profit attributable to shareholders is expected to grow from 3,377 million HKD in 2024 to 3,925 million HKD in 2025, and further to 4,161 million HKD in 2026 [1] - Earnings Per Share (EPS) is forecasted to increase from 0.55 HKD in 2024 to 0.64 HKD in 2025, reaching 0.68 HKD in 2026 [1] - Price-to-Earnings (P/E) ratio is projected to decrease from 9.33 in 2024 to 8.03 in 2025, and further down to 7.57 in 2026 [1]